Search results
Results from the WOW.Com Content Network
(Reuters) - Drugmaker Emergent BioSolutions said on Monday that it would reduce its workforce in Lansing, Michigan, by up to 70 roles as part of its ongoing restructuring efforts.
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. Emergent, which benefits ...
Tuesday, Emergent BioSolutions Inc. (NYSE: ... This new procurement funding is from Emergent’s existing 10-year contract with the Biomedical Advanced Research and Development Authority.
Advanced Bio-Treatment (ABT) is a biohazard response and remediation company operating in twenty-eight states. The company employs a multitude of cleanup teams specializing in crime scene cleanup . Day-to-day business operations are overseen by a customer service driven team from the company’s corporate office located in Jacksonville, Florida .
El-Hibri was the Emergent BioSolutions board of directors executive chairman from April 2012 until shortly before his death. He was both the board chairman and the CEO of the company from 2004 to 2012. He was the board chairman and CEO of BioPort Corporation from 1998 to 2004. Emergent acquired BioPort in 2004. [3]
BAT is the only FDA-approved product available for treating botulism in adults, and for botulism in infants caused by botulinum toxins other than types A and B. BAT has been used to treat a case of type F infant botulism and, on a case-by-case basis, may be used for future cases of non-type A and non-type B infant botulism.
ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence.